Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Neuronetics, a leader in interventional mental health and operator of the Greenbrook interventional psychiatry clinic network, has appointed Nir Naor as Chief Financial Officer, effective July 23, 2026. Naor brings extensive finance and life sciences experience, including past CFO roles at Axogen and Arbor Pharmaceuticals. Additionally, Cory Anders…
Westrock Coffee Company, a global integrated beverage solutions provider, will report its Q2 2026 financial results on August 6 after market close, followed by a live earnings call. The announcement provides investors a comprehensive update on the company's performance across multiple beverage categories and global markets.
ScottsMiracle-Gro Company, a leading North American consumer lawn and garden products marketer, announced it will release its third quarter 2026 financial results on July 29, 2026, before the U.S. market opens. The company will hold a webcast and Q&A session at 8:15 a.m. ET to discuss the results, with registration links provided to investors. Repl…
Ceribell, Inc., a Nasdaq-listed medical technology company specializing in neurological diagnostic devices, announced it will release its second quarter 2026 financial results on August 10, 2026, followed by a management conference call. The company develops the Ceribell System, an AI-powered, portable EEG platform intended for rapid diagnosis and …
TELA Bio, a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, announced it will release its second quarter 2026 financial results on August 10, 2026. Management will hold a conference call and webcast to discuss the results and provide a corporate update.
Rani Therapeutics announced a stock option inducement grant of 2 million shares to its new CFO, Nicholas Maestas, with terms aligning with Nasdaq Listing Rule 5635(c)(4). The option is priced at the closing stock price on the grant date, vests over four years, and aims to incentivize long-term employment.
ServisFirst Bancshares, Inc. (NYSE: SFBS) announced its Q2 2026 financial results, highlighting a 40% increase in diluted earnings per share compared to Q2 2025, driven by robust loan growth and improved net interest margin. Loan balances grew by over $533 million, deposits increased by $686 million, and the company maintained strong capital and li…
Freenome Holdings, an early cancer detection company utilizing AI and multiomics for blood-based screening tests, has completed a business combination with Perceptive Capital Solutions Corp and started trading on Nasdaq under ticker FRNM. The transaction raised over $300 million for fueling R&D, regulatory initiatives, and commercialization, includ…
Gentherm has received FDA 510(k) clearance for its ThermAffyx Patient Safety System, a Class II medical device that integrates active patient warming and securement for robotic-assisted surgeries. Product trials start in August 2026, with revenue expected in Q3 2026. This innovation streamlines surgical patient warming and securement, addressing ga…
Hanover Bancorp, Inc. has announced the appointment of Kevin O’Connor as President of the company and Hanover Community Bank effective July 27, 2026. O’Connor, a seasoned banking executive with over 35 years of experience in the Long Island market, will focus on expanding the bank’s regional presence and strengthening client relationships. His exte…
Cosmos Health Inc. announced an expansion of its partnership with Pharma Cell to distribute its Sky Premium Life brand in Albania. Since launching the partnership in April 2025, monthly orders have surpassed 4,500 units, with expectations of exceeding 54,000 units annually. The products enjoy strong recommendations from doctors nationwide, supporti…
Micron is trading near $866 after a pullback from its spring highs, but fundamentals argue for an upgrade: record-level profitability (EPS $44.69), massive free cash flow ($26.17B), and a fortress-like balance sheet (debt/equity ~0.06) create a pathway to shareholder-friendly capital allocation and a multiple re-rating. That said, aggressive greenf…
Fifth Third's acquisition of Comerica creates a top-10 bank with scale, and the near-term earnings hit from merger costs masks a clear path to margin and expense improvement. I view the stock as a tactical long around $57.45 with a mid-term target of $64.00 and a $51.00 stop while monitoring integration execution and credit trends.
Abercrombie & Fitch (ANF) is trading at a valuation that understates its cash-generation ability and capital return plan. With trailing EPS near $11.11, EV/EBITDA ~4.3 and free cash flow of $416M, ANF looks fundamentally cheap. Recent catalysts - Q1 beat, a Hollister-Target collaboration, and a $450M buyback program - support a mid-term swing trade…
Darline Graham, who was appointed to fill the Senate seat left vacant by the death of her brother Lindsey Graham, has declared she will seek a full term. In a television clip she said she has prayed and consulted family and feels capable despite anticipated challenges. Her announcement follows a direct request from former President Donald Trump to …
Novo Nordisk's shares look poised to continue higher as the company converts injectables momentum into a dominant oral position. Strong prescription share for the oral Wegovy launch, supportive technicals and a reasonable P/E for a market leader create an actionable long trade with clearly defined risk controls.
Dyne Therapeutics is a buy at current levels based on late-stage progress in Duchenne muscular dystrophy (z-rostudirsen), a growing neuromuscular pipeline and a large cash cushion. The trade is speculative and high-risk: the reward hinges on regulatory success and commercialization execution, while free cash flow burn, crowded competition, and mean…
4D Molecular Therapeutics just cleared several execution hurdles: 2-year PRISM Phase 2b data showed strong durability in wet-AMD, Phase 3 is enrolled, and the company has secured non-dilutive capital while locking APAC commercialization through Otsuka. With a market cap near $590M and a cash cushion from an $85M upfront partner payment plus a $200M…
Itochu is likely to use its upcoming IR Day to sharpen capital-allocation messaging. The company has a strong free-cash-flow profile and a history of shareholder returns; a clear commitment to larger buybacks or accelerated returns would re-rate sentiment. This trade targets an entry at $19.50 with a $23.00 target and a $17.00 stop, for a long-term…
UroGen's Zusduri is moving from clinical novelty to commercial staple. Recent reimbursement wins and a sharp revenue ramp ($51M in Q1; +152% YoY) suggest the therapy is being adopted into urology workflows. Given a market cap near $2.01B and elevated short interest, the setup favors a long trade sized for a mid-to-long-term horizon, with clear entr…
Palantir is trading at $136.20 after strong momentum and accelerating commercial adoption. The company sits at the intersection of large-scale data integration, AI orchestration and mission-critical workflows for government and enterprise clients. Fundamentals show positive free cash flow ($2.69B) and high retention metrics cited by analysts; valua…
Tesla is trading at $373.57 with a market cap near $1.40T and stretched multiples, but the macro push to reshore high-value manufacturing combined with early commercial strides in Optimus creates an asymmetric opportunity. This trade targets a re-rating into $460 over the next 180 trading days, with a defined stop at $325 to protect against executi…
Compa Compania de Minas Buenaventura looks undervalued relative to its earnings power and the operational catalysts coming into play. At a current price o…
CAE has traded below its near-term averages while clearing key operational headwinds from 2024 impairments. With recurring training revenue, partnerships (including urban air mobility), and a $7.9B market cap that looks reasonable versus recovery optionality, we upgrade CAE to Strong Buy and lay out a clear entry, stop and target for a long trade o…
Sports Entertainment Gaming Global Corporation (NASDAQ: SEGG) announced that its title-sponsored E1 Team Miami powered by Magnus secured a third-place finish at the E1 Monaco GP, marking the team's first podium of the 2026 season and highlighting the company's growing involvement in electric motorsport and fan engagement through its Sports.com Pred…
